Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles

Cancer Research

Volumn 65, Issue 8, 2005, Pages 3428-3436

  Mortarini, Roberta ^a   Scarito, Alessia ^a   Nonaka, Daisuke ^a   Zanon, Marina ^a   Bersani, Ilaria ^a   Montaldi, Elisabetta ^a   Pennacchioli, Elisabetta ^a   Patuzzo, Roberto ^a   Santinami, Mario ^a   Anichini, Andrea ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCL 21; HERPESVIRUS VECTOR; INTERLEUKIN 2; LIGAND; LYMPHOTOXIN BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; UNCLASSIFIED DRUG;

ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CELL SURFACE; COCULTURE; CONTROLLED STUDY; FREQUENCY ANALYSIS; HUMAN; HUMAN CELL; MEDICAL DOCUMENTATION; MELANOMA; MICROVASCULATURE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; STAINING; STATISTICAL SIGNIFICANCE; STROMA CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

EID: 20244369585     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3239     Document Type: Article

References (48)

1. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136-51.
2. Schwartz RH. T cell anergy. Annu Rev Immunol 2003;21:305-34.
3. Ramirez-Montagut T, Turk MJ, Wolchok JD, Guevara-Patino JA, Houghton AN. Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity. Oncogene 2003;22:3180-7.
4. Steinman RM, Nussenzweig MC. Inaugural Article: avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 2002;99:351-8.
5. + T cells at tumor site in spite of anti-tumor immunity to self antigens in human metastatic melanoma. Cancer Res 2003;63:2535-45.
6. Romero P, Dunbar PR, Valmori D, et al. Ex-vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-50.
7. Morel S, Levy F, Burlet-Schiltz O, et al. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000;12:107-17.
8. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003;3:609-20.
9. Granger SW, Rickert S. LIGHT-HVEM signaling and the regulation of T cell-mediated immunity. Cytokine Growth Factor Rev 2003;14:289-96.
10. Tamada K, Shimozaki K, Chapoval AI, et al. Modulation of T-cell mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathways. Nat Med 2000;6:283-9.
11. Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2004;5:141-9.
12. Mauri DN, Ebner R, Montgomery RI, et al. LIGHT, a new member of the TNF superfamily and lymphotoxin α are ligands for herpesvirus entry mediator. Immunity 1998;8:21-30.
13. Granger SW, Butrovich KD, Houshmand P, Edwards WR, Ware CF. Genomic characterization of LIGHT reveals linkage to an immune response locus on chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis. J Immunol 2001;167:5122-8.
14. Morel Y, Schiano de Colella JM, Harrop J, et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down regulates its own receptor. J Immunol 2000;165:4397-404.
15. Harrop JA, McDonnell PC, Brigham-Burke M, et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 1998;273:27548-56.
16. Ye Q, Fraser CC, Gao W, et al. Modulation of LIGHT-HVEM co-stimulation prolongs cardiac allograft survival. J Exp Med 2002;195:795-800.
17. Tamada K, Shimozaki K, Chapoval AI, et al. LIGHT, a TNF-like molecule, co-stimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000;164:4105-10.
18. Liu J, Schmidt CS, Zhao F, et al. LIGHT-deficiency impairs CD8+ T cell expansion, but not effector function. Int Immunol 2003;15:861-70.
19. Stopfer P, Mannel DN, Hehlgans T. Lymphotoxin-β receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J Immunol 2004;172:7459-65.
20. Anichini A, Molla A, Mortarini R, et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999;190:651-67.
21. Zanon M, Piris A, Bersani I, et al. Apoptosis protease activator protein-1 expression is dispensable for response of human melanoma cells to distinct proapoptotic agents. Cancer Res 2004;64:7386-94.
22. + T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of γc cytokines. J Immunol 2003;171:2135-41.
23. Thery C, Regnault A, Garin J, et al. Molecular characterization of dendritic cell-derived exosomes: selective accumulation of the heat shock protein hsc73. J Cell Biol 1999;147:599-610.
24. Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996;183:1161-72.
25. Andreola G, Rivoltini L, Castelli C, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med 2002;195:1303-16.
26. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/Mart-1 immunodominant peptide analogues. J Immunol 1998;160:1750-8.
27. Kawakami Y, Eliyahu S, Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-52.
28. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
29. Denzer K, Kleijmeer MJ, Heijnen HFG, Stoorvogel W, Geuze HJ. Exosomes: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000;113:3365-74.
30. Chaput N, Taieb J, Schartz NEC, Andrè F, Angevin E, Zitvogel L. Exosome-based immunotherapy. Cancer Immunol Immunother 2004;53:234-9.
31. Clark WH Jr, Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
32. Houghton AN. LIGHTing the way for tumor immunity. Nat Immunol 2004;5:123-4.
33. Lakhani S, Flavell RA. Caspases and T lymphocytes: a flip of the coin? Immunol Rev 2003;193:22-30.
34. Rennert PD, Browning JL, Mebius R, Mackay F, Hochman PS. Surface lymphotoxin α/β complex is required for the development of peripheral lymphoid organs. J Exp Med 1996;184:1999-2006.
35. Futterer A, Mink K, Luz A, Kosco-Vilbois MH, Pfeffer K. The lymphotoxin β receptor control organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998;9:59-70.
36. Endres R, Alimzhanov MB, Plitz T, et al. Mature follicular dendritic cell networks depend on expression of lymphotoxin β receptor by radioresistant stromal cells and of lymphotoxin β and tumor necrosis factor by B cells. J Exp Med 1999;189:159-67.
37. Ngo VN, Korner H, Gunn MD, et al. Lymphotoxin α/β and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 1999;189:403-12.
38. Force WR, Walter BN, Hession C, et al. Mouse lymphotoxin-β receptor. Molecular genetics ligand binding and expression. J Immunol 1995;155:5280-8.
39. Murphy M, Walter BN, Pike-Nobile L, et al. Expression of the lymphotoxin β receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ 1998;5:497-505.
40. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet the soil. Oncogene 2003;22:3162-71.
41. Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DSB. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant melanoma cells. Clin Cancer Res 2004;10:2351-8.
42. Pittet MJ, Valmori D, Dunbar PR, et al. Cross-tolerance: a pathway for inducing tolerance to a peripheral tissue antigens. J Exp Med 1998;187:1549-53.
43. Zhai Y, Guo R, Hsu TL, et al. LIGHT, a novel ligand for lymphotoxin β receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer. J Clin Invest 1998;102:1142-51.
44. Rooney IA, Butrovich KD, Glass AA, et al. The lymphotoxin β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem 2000;275:14307-15.
45. Zhang M, Guo R, Zhai Y, Yang D. LIGHT sensitizes IFN-T-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down regulation of anti-apoptosis Bcl-2 family members. Cancer Lett 2003;195:201-10.
46. Wang J, Fu YX. LIGHT (a cellular ligand for herpes virus entry mediator and lymphotoxin receptor)-mediated thymocyte deletion is dependent on the interaction between TCR and MHC/self peptide. J Immunol 2003;170:3986-93.
47. Costello RT, Mallet F, Schiano de Colella JM, et al. Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity. Leukemia 2003;17:2500-7.
48. Martinez-Lorenzo MJ, Anel A, Alava MA, et al. The human melanoma cell line MelJuSO secretes bioactive FasL and APO/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 2004;295:315-29.